These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 33301196)

  • 1. Challenges in the treatment of a patient with toxic epidermal necrolysis associated with COVID-19: A case report.
    Emadi SN; Hamzelou S; Saffarian Z; Shakoei S
    Dermatol Ther; 2021 Jan; 34(1):e14656. PubMed ID: 33301196
    [No Abstract]   [Full Text] [Related]  

  • 2. COVID-19 infection increases the development of Stevens-Johnson syndrome and toxic epidermal necrolysis: A retrospective cohort analysis.
    Curtis KK; Dillan MM; Sharma TR; Piktel J
    J Am Acad Dermatol; 2024 Jun; 90(6):1300-1302. PubMed ID: 38423469
    [No Abstract]   [Full Text] [Related]  

  • 3. COVID-19-induced toxic epidermal necrolysis.
    Narang I; Panthagani AP; Lewis M; Chohan B; Ferguson A; Nambi R
    Clin Exp Dermatol; 2021 Jul; 46(5):927-929. PubMed ID: 33511662
    [No Abstract]   [Full Text] [Related]  

  • 4. Toxic epidermal necrolysis and Stevens-Johnson syndrome: a review.
    Gerull R; Nelle M; Schaible T
    Crit Care Med; 2011 Jun; 39(6):1521-32. PubMed ID: 21358399
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Toxic epidermal necrolysis (syndrome Lyell) versus Stevens-Johnson syndrome].
    Jezierska-Krupa B; Hyla-Klekot L
    Pediatr Pol; 1996 Jul; 71(7):615-20. PubMed ID: 8803466
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Burn Center Care of Patients with Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis.
    Cartotto R
    Clin Plast Surg; 2017 Jul; 44(3):583-595. PubMed ID: 28576247
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Toxic epidermal necrolysis and Stevens-Johnson syndrome: things we should know!
    Kamolz LP; Spendel S; Prandl EC
    Crit Care Med; 2011 Jun; 39(6):1600-1. PubMed ID: 21610649
    [No Abstract]   [Full Text] [Related]  

  • 8. Development of toxic epidermal necrolysis in a coronavirus disease 2019 patient with recurrence of positive SARS-CoV-2 viral RNA.
    Tanaka A; Isei M; Kikuzawa C; Hinogami H; Nishida K; Gohma I; Ogawa Y
    J Dermatol; 2021 Mar; 48(3):e144-e145. PubMed ID: 33439527
    [No Abstract]   [Full Text] [Related]  

  • 9. Macrophage Activation Syndrome Complicated by Toxic Epidermal Necrolysis Following SARS-CoV-2 mRNA Vaccination.
    Franzblau LE; Mauskar M; Wysocki CA
    J Clin Immunol; 2023 Apr; 43(3):521-524. PubMed ID: 36441289
    [No Abstract]   [Full Text] [Related]  

  • 10. Stevens-Johnson syndrome and toxic epidermal necrolysis.
    Prendiville J
    Adv Dermatol; 2002; 18():151-73. PubMed ID: 12528405
    [No Abstract]   [Full Text] [Related]  

  • 11. Current agreement on the management of Stevens-Johnson syndrome and toxic epidermal necrolysis.
    Chen CB; Chung WH
    Br J Dermatol; 2021 Sep; 185(3):484-486. PubMed ID: 34224137
    [No Abstract]   [Full Text] [Related]  

  • 12. Clinical Features and Management of Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis: A Retrospective Single-Center Study.
    Li Y; Chu Y; Li Q; Li L; Tuo Y; Wang H; Zhang L
    Dermatitis; 2023; 34(2):156-157. PubMed ID: 36730736
    [No Abstract]   [Full Text] [Related]  

  • 13. Toxic epidermal necrolysis: the past, the guidelines and challenges for the future.
    Wolkenstein P; Wilson YT
    Br J Dermatol; 2016 Jun; 174(6):1171-3. PubMed ID: 27317272
    [No Abstract]   [Full Text] [Related]  

  • 14. UK guidelines for the management of Stevens-Johnson syndrome/toxic epidermal necrolysis in adults 2016 (print summary - Full guidelines available at http://dx.doi.org/10.1016/j.bjps.2016.01.034).
    Creamer D; Walsh SA; Dziewulski P; Exton LS; Lee HY; Dart JKG; Setterfield J; Bunker CB; Ardern-Jones MR; Watson KMT; Wong GAE; Philippidou M; Vercueil A; Martin RV; Williams G; Shah M; Brown D; Williams P; Mohd Mustapa MF; Smith CH
    J Plast Reconstr Aesthet Surg; 2016 Jun; 69(6):736-741. PubMed ID: 27216885
    [No Abstract]   [Full Text] [Related]  

  • 15. European Dermatology Forum: skin diseases in Europe. Skin diseases with a high public health impact: toxic epidermal necrolysis and Stevens-Johnson syndrome.
    Fritsch P
    Eur J Dermatol; 2008; 18(2):216-7. PubMed ID: 18424404
    [No Abstract]   [Full Text] [Related]  

  • 16. [Stevens-Johnson syndrome and toxic epidermal necrolysis; therapy policy in these life-threatening illnesses. Netherlands Work Group Toxic Epidermal Necrolysis].
    van der Meer JB
    Ned Tijdschr Geneeskd; 1996 Jul; 140(30):1538-43. PubMed ID: 8765761
    [No Abstract]   [Full Text] [Related]  

  • 17. Toxic epidermal necrolysis.
    Dolan PA; Flowers FP; Araujo OE; Sheretz EF
    J Emerg Med; 1989; 7(1):65-9. PubMed ID: 2649555
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Timing of mucocutaneous symptoms and medication discontinuation in patients with Stevens-Johnson syndrome and toxic epidermal necrolysis in the United States.
    Noe MH; Micheletti RG; Mostaghimi A;
    J Am Acad Dermatol; 2019 Dec; 81(6):1410-1412. PubMed ID: 31085266
    [No Abstract]   [Full Text] [Related]  

  • 19. Toxic Epidermal Necrolysis in a Pediatric Patient.
    Hagen S; Grey K; Hylwa S
    Minn Med; 2016; 99(3):49-50. PubMed ID: 27323526
    [No Abstract]   [Full Text] [Related]  

  • 20. Stevens-Johnson syndrome and toxic epidermal necrolysis-challenges of recognition and management.
    Sane SP; Bhatt AD
    J Assoc Physicians India; 2000 Oct; 48(10):999-1003. PubMed ID: 11200928
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.